Effects of high-intensity progressive resistance training and targeted multidisciplinary treatment of frailty on mortality and nursing home admissions after hip fracture: A randomized controlled trial

Abstract

Rationale: Excess mortality and residual disability are common after hip fracture. Hypothesis: Twelve months of high-intensity weight-lifting exercise and targeted multidisciplinary interventions will result in lower mortality, nursing home admissions, and disability compared with usual care after hip fracture. Design: Randomized, controlled, parallel-group superiority study. Setting: Outpatient clinic. Participants: Patients (n= 124) admitted to public hospital for surgical repair of hip fracture between 2003 and 2007. Intervention: Twelve months of geriatrician-supervised high-intensity weight-lifting exercise and targeted treatment of balance, osteoporosis, nutrition, vitamin D/calcium, depression, cognition, vision, home safety, polypharmacy, hip protectors, self-efficacy, and social support. Outcomes: Functional independence: mortality, nursing home admissions, basic and instrumental activities of daily living (ADLs/IADLs), and assistive device utilization. Results: Risk of death was reduced by 81% (age-adjusted OR [95% CI]= 0.19 [0.04-0.91]; P < .04) in the HIPFIT group (n= 4) compared with usual care controls (n= 8). Nursing home admissions were reduced by 84% (age-adjusted OR [95% CI]= 0.16 [0.04-0.64]; P < .01) in the experimental group (n= 5) compared with controls (n= 12). Basic ADLs declined less (P < .0001) and assistive device use was significantly lower at 12 months (P= .02) in the intervention group compared with controls. The targeted improvements in upper body strength, nutrition, depressive symptoms, vision, balance, cognition, self-efficacy, and habitual activity level were all related to ADL improvements (P < .0001-.02), and improvements in basic ADLs, vision, and walking endurance were associated with reduced nursing home use (P < .0001-.05). Conclusion: The HIPFIT intervention reduced mortality, nursing home admissions, and ADL dependency compared with usual care. Australian New Zealand Clinical Trials Registry (ACTN12605000164695). © 2012 American Medical Directors Association, Inc.